Search

Your search keyword '"Lewis, Basil S."' showing total 1,108 results
Start Over Author "Lewis, Basil S."
1,108 results on '"Lewis, Basil S."'

155. Radial versus femoral access, bleeding and ischemic events in patients with non–ST-segment elevation acute coronary syndrome managed with an invasive strategy

Author

Klutstein, Marc W., Westerhout, Cynthia M., Armstrong, Paul W., Giugliano, Robert P., Lewis, Basil S., Gibson, Michael C., Lutchmedial, Sohrab, Widimsky, Petr, Steg, Gabriel P., Dalby, Anthony, Zeymer, Uwe, Van de Werf, Frans, Harrington, Robert A., Newby, Kristin L., and Rao, Sunil V.

Published
2013
Full Text
View/download PDF

158. Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial.

Author

Bosch, Jackie, Lonn, Eva M., Dagenais, Gilles R., Gao, Peggy, Lopez-Jaramillo, Patricio, Jun Zhu, Pais, Prem, Avezum, Alvaro, Sliwa, Karen, Chazova, Irina E., Peters, Ron J. G., Held, Claes, Yusoff, Khalid, Lewis, Basil S., Toff, William D., Khunti, Kamlesh, Reid, Christopher M., Leiter, Lawrence A., Yusuf, Salim, and Hart, Robert G.

Published
2021
Full Text
View/download PDF

164. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing

Author

El Hadidi, Seif, Rosano, Giuseppe, Tamargo, Juan, Agewall, Stefan, Drexel, Heinz, Kaski, Juan Carlos, Niessner, Alexander, Lewis, Basil S, Coats, Andrew J S, and Savarese, Gianluigi

Abstract

Heart failure (HF) is a chronic debilitating and potentially life-threatening condition. HF patients are usually at high risk of polypharmacy and consequently, potentially inappropriate prescribing leading to poor clinical outcomes. Based on the published literature, a comprehensive HF-specific prescribing review tool is compiled to avoid medications that may cause HF or harm HF patients and to optimize the prescribing practice of HF guideline-directed medical therapies. Recommendations are made in line with the last versions of European Society of Cardiology (ESC) guidelines, ESC position papers, scientific evidence, and experts’ opinions.

Published
2022
Full Text
View/download PDF

165. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

Author

Magavern, Emma Forton, Kaski, Juan Carlos, Turner, Richard M, Drexel, Heinz, Janmohamed, Azara, Scourfield, Andrew, Burrage, Daniel, Floyd, Christopher N, Adeyeye, Elizabeth, Tamargo, Juan, Lewis, Basil S, Kjeldsen, Keld Per, Niessner, Alexander, Wassmann, Sven, Sulzgruber, Patrick, Borry, Pascal, Agewall, Stefan, Semb, Anne Grete, Savarese, Gianluigi, Pirmohamed, Munir, and Caulfield, Mark J

Abstract

There is a strong and ever-growing body of evidence regarding the use of pharmacogenomics to inform cardiovascular pharmacology. However, there is no common position taken by international cardiovascular societies to unite diverse availability, interpretation, and application of such data, nor is there recognition of the challenges of variation in clinical practice between countries within Europe. Aside from the considerable barriers to implementing pharmacogenomic testing and the complexities of clinically actioning results, there are differences in the availability of resources and expertise internationally within Europe. Diverse legal and ethical approaches to genomic testing and clinical therapeutic application also require serious thought. As direct-to-consumer genomic testing becomes more common, it can be anticipated that data may be brought in by patients themselves, which will require critical assessment by the clinical cardiovascular prescriber. In a modern, pluralistic and multi-ethnic Europe, self-identified race/ethnicity may not be concordant with genetically detected ancestry and thus may not accurately convey polymorphism prevalence. Given the broad relevance of pharmacogenomics to areas, such as thrombosis and coagulation, interventional cardiology, heart failure, arrhythmias, clinical trials, and policy/regulatory activity within cardiovascular medicine, as well as to genomic and pharmacology subspecialists, this position statement attempts to address these issues at a wide-ranging level.

Published
2022
Full Text
View/download PDF

166. Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

Author

Magavern, Emma F, Kaski, Juan Carlos, Turner, Richard M, Drexel, Heinz, Janmohamed, Azara, Scourfield, Andrew, Burrage, Daniel, Floyd, Christopher N, Adeyeye, Elizabeth, Tamargo, Juan, Lewis, Basil S, Kjeldsen, Keld Per, Niessner, Alexander, Wassmann, Sven, Sulzgruber, Patrick, Borry, Pascal, Agewall, Stefan, Semb, Anne Grete, Savarese, Gianluigi, Pirmohamed, Munir, and Caulfield, Mark J

Abstract

Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.

Published
2022
Full Text
View/download PDF

167. Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes

Author

Jolly, Sanjit S., Niemelä, Kari, Xavier, Denis, Widimsky, Petr, Budaj, Andrzej, Valentin, Vicent, Lewis, Basil S., Avezum, Alvaro, Steg, Philippe Gabriel, Rao, Sunil V., Cairns, John, Chrolavicius, Susan, Yusuf, Salim, and Mehta, Shamir R.

Published
2011

170. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics

Author

Lonn, Eva, Bosch, Jackie, Pogue, Janice, Avezum, Alvaro, Chazova, Irina, Dans, Antonio, Diaz, Rafael, Fodor, George J., Held, Claes, Jansky, Petr, Keltai, Matyas, Keltai, Katalin, Kunti, Kamlesh, Kim, Jae Hyung, Leiter, Lawrence A., Lewis, Basil S., Liu, Lisheng, Lopez-Jaramillo, Patricio, Pais, Prem, Parkhomenko, Alexander, Peters, Ron J.G., Piegas, Leopoldo S., Reid, Christopher M., Sliwa, Karen, Toff, William D., Varigos, John, Xavier, Denis, Yusoff, Khalid, Zhu, Jun, Dagenais, Gilles, Yusuf, Salim, The HOPE-3 Investigators, Amsterdam Cardiovascular Sciences, Amsterdam Public Health, and Cardiology

Subjects
Male, Tetrazoles, Blood Pressure, 030204 cardiovascular system & hematology, Global Health, law.invention, 0302 clinical medicine, Randomized controlled trial, Risk Factors, law, 030212 general & internal medicine, Myocardial infarction, Rosuvastatin Calcium, Diuretics, Incidence, Middle Aged, Primary Prevention, Cholesterol, Hydrochlorothiazide, Treatment Outcome, Cardiovascular Diseases, Population Surveillance, Blood pressure, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, Cardiovascular Disease Prevention, medicine.drug, medicine.medical_specialty, Statin, medicine.drug_class, COLESTEROL, Placebo, 03 medical and health sciences, Double-Blind Method, Internal medicine, medicine, Humans, Rosuvastatin, Risk factor, Contraindication, Aged, Dose-Response Relationship, Drug, business.industry, Biphenyl Compounds, Cholesterol, LDL, medicine.disease, Surgery, Clinical trial, Benzimidazoles, business, Angiotensin II Type 1 Receptor Blockers
Abstract

8 p., Résumé Introduction Il est possible de faire baisser efficacement et en toute sécurité le cholestérol et la pression artérielle (PA) avec les statines et les antihypertenseurs tout en réduisant de 20 à 30 % les manifestations cardiovasculaires majeures en l’espace de cinq ans chez les personnes à risque élevé. Les données obtenues dans les populations exposées à un risque plus faible sont néanmoins limitées. L’essai HOPE-3 (Heart Outcomes Prevention Evaluation-3) tâche de déterminer si l’abaissement du cholestérol à l’aide d’une statine, l’abaissement de la pression artérielle à l’aide de deux agents antihypertenseurs administrés à raison d’une faible dose et leur association permettent de réduire en toute sécurité les manifestations cardiovasculaires majeures chez les personnes exposées à un risque intermédiaire qui n’ont pas d’antécédents d’événements vasculaires et dont le taux de cholestérol et la PA se situent dans la moyenne. Méthodes Au total, 12 705 femmes et hommes, les unes âgées de 65 ans et plus et les autres de 55 ans et plus, qui présentent au moins un facteur de risque cardiovasculaire et qui n’ont pas de maladie cardiovasculaire connue ni aucune indication ou contre-indication claires aux médicaments à l’étude, ont été répartis aléatoirement pour recevoir de la rosuvastatine à raison de 10 mg par jour ou un placebo et l’association candésartan/hydrochlorothiazide à raison de 16/12,5 mg par jour ou un placebo (plan factoriel 2 × 2). Ces patients seront suivis pendant une moyenne de 5,8 ans. Les principaux paramètres d’évaluation de l’étude combinent le décès d’origine cardiovasculaire, l’infarctus du myocarde non mortel et l’AVC non mortel d’une part, et le décès d’origine cardiovasculaire, l’infarctus du myocarde non mortel, l’AVC non mortel, la réanimation après arrêt cardiaque, l’insuffisance cardiaque et la revascularisation artérielle d’autre part. Résultats Les participants ont été recrutés dans 21 pays situés en Amérique du Nord, en Amérique du Sud, en Europe, en Asie et en Australie. L’âge moyen au moment de la répartition aléatoire était de 66 ans, et 46 % des sujets étaient des femmes. Conclusions L’essai HOPE-3 fournira de nouveaux renseignements sur l’abaissement du taux de cholestérol et de la PA dans des populations exposées à un risque intermédiaire dont le taux de cholestérol et la PA se situent dans la moyenne. Il devrait également fournir des données à l’appui des stratégies de prévention primaire mises en place partout dans le monde (HOPE-3 ClinicalTrials.gov NCT00468923)., Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular (CV) events by 20%-30% within 5 years in high-risk individuals. However, there are limited data in lower-risk populations. The Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial is evaluating whether cholesterol lowering with a statin drug, BP lowering with low doses of 2 antihypertensive agents, and their combination safely reduce major CV events in individuals at intermediate risk who have had no previous vascular events and have average cholesterol and BP levels. Methods A total of 12,705 women 65 years or older and men 55 years or older with at least 1 CV risk factor, no known CV disease, and without any clear indication or contraindication to the study drugs were randomized to rosuvastatin 10 mg/d or placebo and to candesartan/hydrochlorothiazide 16/12.5 mg/d or placebo (2 × 2 factorial design) and will be followed for a mean of 5.8 years. The coprimary study outcomes are the composite of CV death, nonfatal myocardial infarction (MI), and nonfatal stroke and the composite of CV death, nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, heart failure, and arterial revascularization. Results Participants were recruited from 21 countries in North America, South America, Europe, Asia, and Australia. Mean age at randomization was 66 years and 46% were women. Conclusions The HOPE-3 trial will provide new information on cholesterol and BP lowering in intermediate-risk populations with average cholesterol and BP levels and is expected to inform approaches to primary prevention worldwide (HOPE-3 ClinicalTrials.gov NCT00468923).

Published
2016

172. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58.

Author

Zelniker, Thomas A., Morrow, David A., Mosenzon, Ofri, Goodrich, Erica L., Jarolim, Petr, Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John, Bode, Christoph, Lewis, Basil S., Gause‐Nilsson, Ingrid, Langkilde, Anna Maria, Fredriksson, Martin, Raz, Itamar, Sabatine, Marc S., and Wiviott, Stephen D.

Subjects
DAPAGLIFLOZIN, HEART failure, CARDIOVASCULAR disease related mortality, TYPE 2 diabetes
Abstract

Aims: Dapagliflozin reduced the risk of the composite of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus in DECLARE‐TIMI 58. We hypothesized that baseline N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity troponin T (hsTnT) levels would help identify patients who are at higher baseline risk and we describe the treatment effects of dapagliflozin in patients according to their baseline NT‐proBNP and hsTnT levels. Methods and results: This was a pre‐specified biomarker study from DECLARE‐TIMI 58, a randomized, double‐blind, placebo‐controlled CV outcomes trial of dapagliflozin. Baseline NT‐proBNP and hsTnT levels were measured in the TIMI Clinical Trials Laboratory in 14 565 patients. Among the included patients, 9143 patients (62.8%) were male, 1464 (10.1%) had a history of heart failure and the mean age was 63.9 years. The median baseline NT‐proBNP and hsTnT levels were 75 pg/mL [interquartile range (IQR) 35–165] and 10.2 pg/mL (IQR 6.9–15.5), respectively. Patients with higher NT‐proBNP and hsTnT quartiles had higher rates of CV death/HHF (Q4 vs. Q1: NT‐proBNP: 4‐year Kaplan–Meier event rates 13.7% vs. 1.0%; hsTnT: 11.8% vs. 1.4%; P‐trend <0.001). Dapagliflozin consistently reduced the relative risk of CV death/HHF regardless of baseline NT‐proBNP (P‐interaction 0.72) or hsTnT quartiles (P‐interaction 0.93). Given their higher baseline risk, patients with NT‐proBNP and/or hsTnT levels above the median derived larger absolute risk reductions with dapagliflozin (NT‐proBNP 1.9% vs. 0%, P‐interaction 0.010; hsTnT 1.8% vs. 0.1%, P‐interaction 0.026). Conclusion: Patients with type 2 diabetes mellitus and higher NT‐proBNP or hsTnT levels are at increased risk of CV death and HHF. Dapagliflozin reduced the relative risk of CV death/HHF irrespective of NT‐proBNP and hsTnT levels, with greater absolute risk reductions seen in patients with higher baseline biomarker levels. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

173. Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.

Author

Carnicelli, Anthony P., Al-Khatib, Sana M., Xavier, Denis, Dalgaard, Frederik, Merrill, Peter D., Wojdyla, Daniel M., Lewis, Basil S., Hanna, Michael, Alexander, John H., Lopes, Renato D., Wallentin, Lars, and Granger, Christopher B.

Subjects
TRANSIENT ischemic attack, ATRIAL fibrillation, WARFARIN, APIXABAN, THROMBOEMBOLISM prevention, PYRIDINE, RESEARCH, HETEROCYCLIC compounds, ORAL drug administration, TIME, RESEARCH methodology, WORLD health, DISEASE incidence, PROGNOSIS, ANTICOAGULANTS, MEDICAL cooperation, EVALUATION research, RISK assessment, TREATMENT effectiveness, DRUG administration, COMPARATIVE studies, DOSE-effect relationship in pharmacology, THROMBOEMBOLISM, BLIND experiment, PASSIVE euthanasia, LONGITUDINAL method, DISEASE complications
Abstract

Aims: The ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial randomised patients with atrial fibrillation at risk of stroke to apixaban or warfarin. We sought to describe patients from ARISTOTLE who prematurely permanently discontinued study drug.Methods/results: We performed a posthoc analysis of patients from ARISTOTLE who prematurely permanently discontinued study drug during the study or follow-up period. Discontinuation rates and reasons for discontinuation were described. Death, thromboembolism (stroke, transient ischaemic attack, systemic embolism), myocardial infarction and major bleeding rates were stratified by ≤30 days or >30 days after discontinuation. A total of 4063/18 140 (22.4%) patients discontinued study drug at a median of 7.3 (2.2, 15.2) months after randomisation. Patients with discontinuation were more likely to be female and had a higher prevalence of cardiovascular disease, diabetes, renal impairment and anaemia. Premature permanent discontinuation was more common in those randomised to warfarin than apixaban (23.4% vs 21.4%; p=0.002). The most common reasons for discontinuation were patient request (46.1%) and adverse event (34.9%), with no significant difference between treatment groups. The cumulative incidence of clinical events ≤30 days after premature permanent discontinuation for all-cause death, thromboembolism, myocardial infarction, and major bleeding was 5.8%, 2.6%, 0.9%, and 3.0%, respectively. No significant difference was seen between treatment groups with respect to clinical outcomes after discontinuation.Conclusion: Premature permanent discontinuation of study drug in ARISTOTLE was common, less frequent in patients receiving apixaban than warfarin and was followed by high 30-day rates of death, thromboembolism and major bleeding. Initiatives are needed to reduce discontinuation of oral anticoagulation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

175. Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1

Author

Sulzgruber, Patrick, primary, Wassmann, Sven, additional, Semb, Anne Grete, additional, Doehner, Wolfram, additional, Widimsky, Petr, additional, Gremmel, Thomas, additional, Kaski, Juan Carlos, additional, Savarese, Gianluigi, additional, Rosano, Giuseppe M C, additional, Borghi, Claudio, additional, Kjeldsen, Keld, additional, Torp-Pedersen, Christian, additional, Schmidt, Thomas Andersen, additional, Lewis, Basil S, additional, Drexel, Heinz, additional, Tamargo, Juan, additional, Atar, Dan, additional, Agewall, Stefan, additional, and Niessner, Alexander, additional

Published
2019
Full Text
View/download PDF

176. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology

Author

Seferovic, Petar M., primary, Ponikowski, Piotr, additional, Anker, Stefan D., additional, Bauersachs, Johann, additional, Chioncel, Ovidiu, additional, Cleland, John G.F., additional, de Boer, Rudolf A., additional, Drexel, Heinz, additional, Ben Gal, Tuvia, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Jankowska, Ewa A., additional, Anker, Markus S., additional, Lainscak, Mitja, additional, Lewis, Basil S., additional, McDonagh, Theresa, additional, Metra, Marco, additional, Milicic, Davor, additional, Mullens, Wilfried, additional, Piepoli, Massimo F., additional, Rosano, Giuseppe, additional, Ruschitzka, Frank, additional, Volterrani, Maurizio, additional, Voors, Adriaan A., additional, Filippatos, Gerasimos, additional, and Coats, Andrew J.S., additional

Published
2019
Full Text
View/download PDF

177. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials

Author

Drexel, Heinz, primary, Rosano, Giuseppe M C, additional, Lewis, Basil S, additional, Huber, Kurt, additional, Vonbank, Alexander, additional, Dopheide, Jörn F, additional, Mader, Arthur, additional, Niessner, Alexander, additional, Savarese, Gianluigi, additional, Wassmann, Sven, additional, and Agewall, Stefan, additional

Published
2019
Full Text
View/download PDF

178. Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases

Author

Savarese, Gianluigi, primary, Reiner, Martin F, additional, Uijl, Alicia, additional, D’Amario, Domenico, additional, Agewall, Stefan, additional, Atar, Dan, additional, Baumgartner, Iris, additional, Borghi, Claudio, additional, De Carlo, Marco, additional, Drexel, Heinz, additional, Kaski, Juan Carlos, additional, Kjeldsen, Keld P, additional, Kucher, Nils, additional, Lund, Lars H, additional, Niessner, Alexander, additional, Semb, Anne Grete, additional, Schmidt, Thomas A, additional, Sulzgruber, Patrick, additional, Tamargo, Juan, additional, Vitale, Cristiana, additional, Wassmann, Sven, additional, Aboyans, Victor, additional, and Lewis, Basil S, additional

Published
2019
Full Text
View/download PDF

180. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial

Author

Guimarães, Patricia O., primary, Pokorney, Sean D., additional, Lopes, Renato D., additional, Wojdyla, Daniel M., additional, Gersh, Bernard J., additional, Giczewska, Anna, additional, Carnicelli, Anthony, additional, Lewis, Basil S., additional, Hanna, Michael, additional, Wallentin, Lars, additional, Vinereanu, Dragos, additional, Alexander, John H., additional, and Granger, Christopher B., additional

Published
2019
Full Text
View/download PDF

181. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction

Author

Gibson, C. Michael, primary, Kerneis, Mathieu, additional, Yee, Megan K., additional, Daaboul, Yazan, additional, Korjian, Serge, additional, Mehr, Ali Poyan, additional, Tricoci, Pierluigi, additional, Alexander, John H., additional, Kastelein, John J.P., additional, Mehran, Roxana, additional, Bode, Christoph, additional, Lewis, Basil S., additional, Mehta, Ravindra, additional, Duffy, Danielle, additional, Feaster, John, additional, Halabi, Majdi, additional, Angiolillo, Dominick J., additional, Duerschmied, Daniel, additional, Ophuis, Ton Oude, additional, and Merkely, Bela, additional

Published
2019
Full Text
View/download PDF

185. Usefulness of late potentials on the immediate postoperative signal-averaged electrocardiogram in predicting ventricular tachyarrhythmias early after isolated coronary artery bypass grafting

Author

Elami, Amir, Merin, Gideon, Flugelman, Moshe Y., Adar, Lyorit, Rudis, Ehud, Halon, David A., and Lewis, Basil S.

Subjects
Coronary artery bypass -- Complications, Ventricular tachycardia -- Diagnosis, Electrocardiography -- Evaluation, Health
Abstract

The present study was undertaken to determine the value of abnormal late ventricular potentials on signal-averaged electrocardiograms (ECG) in identifying patients at risk of developing ventricular tachycardia or ventricular fibrillation in the early postoperative period after coronary artery bypass grafting, Signal-averaged ECGs were recorded immediately after operation in 72 patients. Abnormal late potentials were defined as the presence of 2 or 3 of the following: (1) root-mean-square amplitude of the last 40 ms of the QRS 120 ms (in patients with conduction defects, only the first 2 criteria were used). Abnormal late ventricular potentials were present on the immediate postoperative signal-averaged ECG in 26 of the 72 patients (36%). Life-threatening ventricular tachyarrhythmias occurred in 6 patients. Late potentials were present in all 6 patients, but only in 20 of 66 (30%) who did not develop ventricular tachyarrhythmias (p

Published
1994

188. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)

Author

Roffi, Marco, Patrono, Carlo, Collet, Jean-Philippe, Mueller, Christian, Valgimigli, Marco, Andreotti, Felicita, Bax, Jeroen J, Borger, Michael A, Brotons, Carlos, Chew, Derek P, Gencer, Baris, Hasenfuss, Gerd, Kjeldsen, Keld, Lancellotti, Patrizio, Landmesser, Ulf, Mehilli, Julinda, Mukherjee, Debabrata, Storey, Robert F, Windecker, Stephan, Patrono, Marco, Baumgartner, Helmut, Gaemperli, Oliver, Achenbach, Stephan, Agewall, Stefan, Badimon, Lina, Baigent, Colin, Bueno, Héctor, Bugiardini, Raffaele, Carerj, Scipione, Casselman, Filip, Cuisset, Thomas, Erol, Çetin, Fitzsimons, Donna, Halle, Martin, Hamm, Christian, Hildick-Smith, David, Huber, Kurt, Iliodromitis, Efstathios, James, Stefan, Lewis, Basil S, Lip, Gregory y H, Piepoli, Massimo F, Richter, Dimitrios, Rosemann, Thomas, Sechtem, Udo, Steg, Ph Gabriel, Vrints, Christian, Luis Zamorano, Jose, Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Roffi, Marco, Patrono, Carlo, Collet, Jean-Philippe, Mueller, Christian, Valgimigli, Marco, Andreotti, Felicita, Bax, Jeroen J, Borger, Michael A, Brotons, Carlo, Chew, Derek P, Gencer, Bari, Hasenfuss, Gerd, Kjeldsen, Keld, Lancellotti, Patrizio, Landmesser, Ulf, Mehilli, Julinda, Mukherjee, Debabrata, Storey, Robert F, Windecker, Stephan, Baumgartner, Helmut, Gaemperli, Oliver, Achenbach, Stephan, Agewall, Stefan, Badimon, Lina, Baigent, Colin, Bueno, Héctor, Bugiardini, Raffaele, Carerj, Scipione, Casselman, Filip, Cuisset, Thoma, Erol, Çetin, Fitzsimons, Donna, Halle, Martin, Hamm, Christian, Hildick-Smith, David, Huber, Kurt, Iliodromitis, Efstathio, James, Stefan, Lewis, Basil S, Lip, Gregory Y H, Piepoli, Massimo F, Richter, Dimitrio, Rosemann, Thoma, Sechtem, Udo, Steg, Ph Gabriel, Vrints, Christian, Luis Zamorano, Jose, ACS - Amsterdam Cardiovascular Sciences, APH - Amsterdam Public Health, and Cardiology

Subjects
High-sensitivity troponin, Ticagrelor, Chest pain unit, medicine.medical_treatment, Atherothrombosis, Myocardial ischaemia, Recommendations, MESH: Risk Assessment, Early invasive strategy, Electrocardiography, Acute cardiac care, Acute coronary syndromes, Angioplasty, Anticoagulation, Apixaban, Aspirin, Beta-blockers, Bivalirudin, Bypass surgery, Cangrelor, Clopidogrel, Dabigatran, Diabetes, Enoxaparin, European society of cardiology, Fondaparinux, Glycoprotein IIb/IIIa inhibitors, Guidelines, Heparin, Nitrates, Non-ST-elevation myocardial infarction, Platelet inhibition, Prasugrel, Revascularization, Rhythm monitoring, Rivaroxaban, Statin, Stent, Unstable angina, Vorapaxar, Cardiology and Cardiovascular Medicine, ST segment, Myocardial infarction, 610 Medicine & health, ComputingMilieux_MISCELLANEOUS, MESH: Platelet Glycoprotein GPIIb-IIIa Complex, Platelet aggregation inhibitor, MESH: Percutaneous Coronary Intervention, MESH: Hemorrhage, medicine.medical_specialty, Acute coronary syndrome, Cardiotonic Agents, MESH: Algorithms, Hemorrhage, Platelet Glycoprotein GPIIb-IIIa Complex, MESH: Anticoagulants, Risk Assessment, Percutaneous Coronary Intervention, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Humans, Acute Coronary Syndrome, Physical Examination, Management of acute coronary syndrome, MESH: Humans, MESH: Cardiotonic Agents, Recommendation, medicine.disease, MESH: Acute Coronary Syndrome, Long-Term Care, MESH: Coronary Angiography, MESH: Non-ST Elevated Myocardial Infarction, Purinergic P2Y Receptor Antagonists, Human medicine, Biomarkers, Guideline, Diabete, Nitrate, Coronary Angiography, MESH: Angina Pectoris, MESH: Long-Term Care, Non-ST Elevated Myocardial Infarction, reproductive and urinary physiology, Atherothrombosi, MESH: Platelet Aggregation Inhibitors, embryonic structures, Cardiology, MESH: Purinergic P2Y Receptor Antagonists, biological phenomena, cell phenomena, and immunity, Algorithms, medicine.drug, Settore BIO/14 - FARMACOLOGIA, Glycoprotein IIb/IIIa inhibitor, European Society of Cardiology, Angina Pectoris, Diagnosis, Differential, MESH: Physical Examination, MESH: Diagnosis, Differential, Internal medicine, medicine, Beta-blocker, urogenital system, business.industry, Percutaneous coronary intervention, Anticoagulants, MESH: Electrocardiography, MESH: Biomarkers, business, Platelet Aggregation Inhibitors
Abstract

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).

Published
2015

189. Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST

Author

Roffi, Marco, Patrono, Carlo, Collet, Jean Philippe, Mueller, Christian, Valgimigli, Marco, Andreotti, Felicita, Bax, Jeroen J., Borger, Michael A., Brotons, Carlos, Chew, Derek P., Gencer, Baris, Hasenfuss, Gerd, Kjeldsen, Keld, Lancellotti, Patrizio, Landmesser, Ulf, Mehilli, Julinda, Mukherjee, Debabrata, Storey, Robert F., Windecker, Stephan, Baumgartner, Helmut, Gaemperli, Oliver, Achenbach, Stephan, Agewall, Stefan, Badimon, Lina, Baigent, Colin, Bueno, Héctor, Bugiardini, Raffaele, Carerj, Scipione, Casselman, Filip, Cuisset, Thomas, Erol, Çetin, Fitzsimons, Donna, Halle, Martin, Hamm, Christian, Hildick Smith, David, Huber, Kurt, Iliodromitis, Efstathios, James, Stefan, Lewis, Basil S., Lip, Gregory Y. H., Piepoli, Massimo F., Richter, Dimitrios, Rosemann, Thomas, Sechtem, Udo, Steg, P. h. Gabriel, Vrints, Christian, Zamorano, José Luis, Roffi, Marco, Patrono, Carlo, Collet, Jean-Philippe, Mueller, Christian, Valgimigli, Marco, Andreotti, Felicita, Bax, Jeroen J., Borger, Michael A., Brotons, Carlo, Chew, Derek P., Gencer, Bari, Hasenfuss, Gerd, Kjeldsen, Keld, Lancellotti, Patrizio, Landmesser, Ulf, Mehilli, Julinda, Mukherjee, Debabrata, Storey, Robert F., Windecker, Stephan, Baumgartner, Helmut, Gaemperli, Oliver, Achenbach, Stephan, Agewall, Stefan, Mendieta Badimon, Lina Guiomar, Baigent, Colin, Bueno, Héctor, Bugiardini, Raffaele, Carerj, Scipione, Casselman, Filip, Cuisset, Thoma, Erol, Çetin, Fitzsimons, Donna, Halle, Martin, Hamm, Christian, Hildick-Smith, David, Huber, Kurt, Iliodromitis, Efstathio, James, Stefan, Lewis, Basil S., Lip, Gregory Y.H., Piepoli, Massimo F., Richter, Dimitrio, Rosemann, Thoma, Sechtem, Udo, Steg, Ph. Gabriel, Vrints, Christian, and Zamorano, José Luis

Subjects
Cardiology and Cardiovascular Medicine
Abstract

N/A

Published
2015

190. Nitrate tolerance in heart failure: differential venous, pulmonary and systemic arterial effects

Author

Makhoul, Nabeel, Dakak, Nader, Flugelman, Moshe Y., Merdler, Amnon, Shefer, Arie, Schneeweiss, Adam, Halon, David A., and Lewis, Basil S.

Subjects
Drug tolerance -- Analysis, Nitroglycerin -- Health aspects, Congestive heart failure -- Drug therapy, Health
Abstract

The hemodynamic profile of tolerance to intravenous nitroglycerin was studied in 9 patients with New York Heart Association Class III to IV congestive heart failure. After rapid dosage build-up to the maximal tolerated dose (decrease in pulmonary wedge Pressure to 10 mm Hg or systolic blood pressure to 90 mm Hg), nitroglycerin (525 [+/-] 548 [mu]g/min) was administered at a constant continuous intravenous infusion for a total of 24 hours. The extent of nitrate tolerance at 24 hours was calculated as the percentage loss of the benefit achieved at time of peak effect of nitroglycerin. Tolerance had a different time course and magnitude in the venous, arterial and pulmonary circulations. At 24 hours, right atrial pressure and pulmonary vascular resistance returned to control values in most patients, while 40 to 50% of the effect on systemic vascular resistance, cardiac index and pulmonary wedge pressure was maintained. These findings emphasize the importance of precise definitions in studies relating to nitrate tolerance. (Am J Cardiol 1990;65:28J-31J), Congestive heart failure is the inability of the heart to pump blood, which leads to congestion of fluid within the lungs. It can be treated with nitrate drugs, which dilate blood vessels. However, nitrate treatment may result in drug tolerance or decreased effectiveness, which interferes with the beneficial effects of these agents in the treatment of congestive heart failure. The characteristics of tolerance, which developed during intravenous therapy with the nitrate agent nitroglycerin, were assessed in nine patients in advanced stages of congestive heart failure. The maximal tolerated dose of nitroglycerin was given, followed by continuous intravenous administration of the drug for 24 hours. Nitrate tolerance at 24 hours was determined as the percentage of loss of beneficial effect at the time of peak or maximal effect of nitroglycerin. After 24 hours, the pressure in the right atrium (upper chamber) of the heart and pulmonary vascular resistance, the pressure against blood flow in the lungs, returned to pre-treatment values. However, improvements in systemic vascular resistance, the pressure opposing blood flow in the peripheral circulation; cardiac index, a measure of amount of blood pumped by the heart; and pulmonary wedge pressure, a measure of pressures within the left ventricle and left atrium (chambers of the heart), were partially maintained after 24 hours. The results show the importance of specifically defining nitrate tolerance in studies examining this complication of nitrate therapy. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

191. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review

Author

Vonbank, Alexander, primary, Drexel, Heinz, additional, Agewall, Stefan, additional, Lewis, Basil S, additional, Dopheide, Joern F, additional, Kjeldsen, Keld, additional, Ceconi, Claudio, additional, Savarese, Gianluigi, additional, Rosano, Giuseppe, additional, Wassmann, Sven, additional, Niessner, Alexander, additional, Schmidt, Thomas Andersen, additional, Saely, Christoph H, additional, Baumgartner, Iris, additional, and Tamargo, Juan, additional

Published
2018
Full Text
View/download PDF

193. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

Author

Rosano, Giuseppe M C, primary, Tamargo, Juan, additional, Kjeldsen, Keld P, additional, Lainscak, Mitja, additional, Agewall, Stefan, additional, Anker, Stefan D, additional, Ceconi, Claudio, additional, Coats, Andrew J S, additional, Drexel, Heinz, additional, Filippatos, Gerasimos, additional, Kaski, Juan Carlos, additional, Lund, Lars, additional, Niessner, Alexander, additional, Ponikowski, Piotr, additional, Savarese, Gianluigi, additional, Schmidt, Thomas A, additional, Seferovic, Petar, additional, Wassmann, Sven, additional, Walther, Thomas, additional, and Lewis, Basil S, additional

Published
2018
Full Text
View/download PDF

194. Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE

Author

Goto, Shinya, primary, Merrill, Peter, additional, Wallentin, Lars, additional, Wojdyla, Daniel M, additional, Hanna, Michael, additional, Avezum, Alvaro, additional, Easton, J Donald, additional, Harjola, Veli-Pekka, additional, Huber, Kurt, additional, Lewis, Basil S, additional, Parkhomenko, Alexander, additional, Zhu, Jun, additional, Granger, Christopher B, additional, Lopes, Renato D, additional, and Alexander, John H, additional

Published
2018
Full Text
View/download PDF

195. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease

Author

Vinereanu, Dragos, primary, Wang, Alice, additional, Mulder, Hillary, additional, Lopes, Renato D, additional, Jansky, Petr, additional, Lewis, Basil S, additional, Gersh, Bernard J, additional, Avezum, Alvaro, additional, Hanna, Michael, additional, Held, Claes, additional, Wallentin, Lars, additional, Granger, Christopher B, additional, and Alexander, John H, additional

Published
2018
Full Text
View/download PDF

196. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Author

Anand, Sonia S, primary, Bosch, Jackie, additional, Eikelboom, John W, additional, Connolly, Stuart J, additional, Diaz, Rafael, additional, Widimsky, Peter, additional, Aboyans, Victor, additional, Alings, Marco, additional, Kakkar, Ajay K, additional, Keltai, Katalin, additional, Maggioni, Aldo P, additional, Lewis, Basil S, additional, Störk, Stefan, additional, Zhu, Jun, additional, Lopez-Jaramillo, Patricio, additional, O'Donnell, Martin, additional, Commerford, Patrick J, additional, Vinereanu, Dragos, additional, Pogosova, Nana, additional, Ryden, Lars, additional, Fox, Keith A A, additional, Bhatt, Deepak L, additional, Misselwitz, Frank, additional, Varigos, John D, additional, Vanassche, Thomas, additional, Avezum, Alvaro A, additional, Chen, Edmond, additional, Branch, Kelley, additional, Leong, Darryl P, additional, Bangdiwala, Shrikant I, additional, Hart, Robert G, additional, Yusuf, Salim, additional, SALA, JORGELINA, additional, CARTASEGNA, LUIS, additional, VICO, MARISA, additional, HOMINAL, MIGUEL ANGEL, additional, HASBANI, EDUARDO, additional, CACCAVO, ALBERTO, additional, ZAIDMAN, CESAR, additional, VOGEL, DANIEL, additional, HRABAR, ADRIAN, additional, SCHYGIEL, PABLO OMAR, additional, CUNEO, CARLOS, additional, LUQUEZ, HUGO, additional, MACKINNON, IGNACIO J., additional, AHUAD GUERRERO, RODOLFO ANDRES, additional, COSTABEL, JUAN PABLO, additional, BARTOLACCI, INES PALMIRA, additional, MONTANA, OSCAR, additional, BARBIERI, MARIA, additional, GOMEZ VILAMAJO, OSCAR, additional, GARCIA DURAN, RUBEN OMAR, additional, SCHIAVI, LILIA BEATRIZ, additional, GARRIDO, MARCELO, additional, INGARAMO, ADRIAN, additional, BORDONAVA, ANSELMO PAULINO, additional, PELAGAGGE, MARIA JOSE, additional, NOVARETTO, LEONARDO, additional, ALBISU DI GENNERO, JUAN PABLO, additional, IBANEZ SAGGIA, LUZ MARIA, additional, ALVAREZ, MOIRA, additional, VITA, NESTOR ALEJANDRO, additional, MACIN, STELLA MARIS, additional, DRAN, RICARDO DARIO, additional, CARDONA, MARCELO, additional, GUZMAN, LUIS, additional, SARJANOVICH, RODOLFO JUAN, additional, CUADRADO, JESUS, additional, NANI, SEBASTIAN, additional, LITVAK BRUNO, MARCOS RAUL, additional, CHACON, CAROLINA, additional, MAFFEI, LAURA ELENA, additional, GRINFELD, DIEGO, additional, VENSENTINI, NATALIA, additional, MAJUL, CLAUDIO RODOLFO, additional, LUCIARDI, HECTOR LUCAS, additional, GONZALEZ COLASO, PATRICIA DEL CARMEN, additional, FERRE PACORA, FREDY ANTONI, additional, VAN DEN HEUVEL, PAUL, additional, VERHAMME, PETER, additional, ECTOR, BAVO, additional, DEBONNAIRE, PHILIPPE, additional, VAN DE BORNE, PHILIPPE, additional, LEROY, JEAN, additional, SCHROE, HERMAN, additional, VRANCKX, PASCAL, additional, ELEGEERT, IVAN, additional, HOFFER, ETIENNE, additional, DUJARDIN, KARL, additional, INDIO DO BRASIL, CLARISSE, additional, PRECOMA, DALTON, additional, ABRANTES, JOSE ANTONIO, additional, MANENTI, EULER, additional, REIS, GILMAR, additional, SARAIVA, JOSE, additional, MAIA, LILIA, additional, HERNANDES, MAURO, additional, ROSSI, PAULO, additional, ROSSI DOS SANTOS, FABIO, additional, ZIMMERMANN, SERGIO LUIZ, additional, RECH, RAFAEL, additional, ABIB JR, EDUARDO, additional, LEAES, PAULO, additional, BOTELHO, ROBERTO, additional, DUTRA, OSCAR, additional, SOUZA, WEIMAR, additional, BRAILE, MARIA, additional, IZUKAWA, NILO, additional, NICOLAU, JOSE CARLOS, additional, TANAJURA, LUIZ FERNANDO, additional, SERRANO JUNIOR, CARLOS VICENTE, additional, MINELLI, CESAR, additional, NASI, LUIZ ANTONIO, additional, OLIVEIRA, LIVIA, additional, DE CARVALHO CANTARELLI, MARCELO JOSE, additional, TYTUS, RICHARD, additional, PANDEY, SHEKHAR, additional, LONN, EVA, additional, CHA, JAMES, additional, VIZEL, SAUL, additional, BABAPULLE, MOHAN, additional, LAMY, ANDRE, additional, SAUNDERS, KEVIN, additional, BERLINGIERI, JOSEPH, additional, KIAII, BOB, additional, BHARGAVA, RAKESH, additional, MEHTA, PRAVINSAGAR, additional, HILL, LAURIE, additional, FELL, DAVID, additional, LAM, ANDY, additional, AL-QOOFI, FAISAL, additional, BROWN, CRAIG, additional, PETRELLA, ROBERT, additional, RICCI, JOSEPH A, additional, GLANZ, ANTHONY, additional, NOISEUX, NICOLAS, additional, BAINEY, KEVIN, additional, MERALI, FATIMA, additional, HEFFERNAN, MICHAEL, additional, DELLA SIEGA, ANTHONY, additional, DAGENAIS, GILLES R, additional, DAGENAIS, FRANCOIS, additional, BRULOTTE, STEEVE, additional, NGUYEN, MICHEL, additional, HARTLEIB, MICHAEL, additional, GUZMAN, RANDOLPH, additional, BOURGEOIS, RONALD, additional, RUPKA, DENNIS, additional, KHAYKIN, YAARIV, additional, GOSSELIN, GILBERT, additional, HUYNH, THAO, additional, PILON, CLAUDE, additional, CAMPEAU, JEAN, additional, PICHETTE, FRANCIS, additional, DIAZ, ARIEL, additional, JOHNSTON, JAMES, additional, SHUKLE, PRAVIN, additional, HIRSCH, GREGORY, additional, RHEAULT, PAUL, additional, CZARNECKI, WLODZIMIERZ, additional, ROY, ANNIE, additional, NAWAZ, SHAH, additional, FREMES, STEPHEN, additional, SHUKLA, DINKAR, additional, JANO, GABRIEL, additional, COBOS, JORGE LEONARDO, additional, CORBALAN, RAMON, additional, MEDINA, MARCELO, additional, NAHUELPAN, LEONARDO, additional, RAFFO, CARLOS, additional, PEREZ, LUIS, additional, POTTHOFF, SERGIO, additional, STOCKINS, BENJAMIN, additional, SEPULVEDA, PABLO, additional, PINCETTI, CHRISTIAN, additional, VEJAR, MARGARITA, additional, TIAN, HONGYAN, additional, WU, XUESI, additional, KE, YUANNAN, additional, JIA, KAIYING, additional, YIN, PENGFEI, additional, WANG, ZHAOHUI, additional, YU, LITIAN, additional, WU, SHULIN, additional, WU, ZONGQUI, additional, LIU, SHAO WEN, additional, BAI, XIAO JUAN, additional, ZHENG, YANG, additional, YANG, PING, additional, YANG, YUN MEI, additional, ZHANG, JIWEI, additional, GE, JUNBO, additional, CHEN, XIAO PING, additional, LI, JUNXIA, additional, HU, TAO HONG, additional, ZHANG, RUIYAN, additional, ZHENG, ZHE, additional, CHEN, XIN, additional, TAO, LIANG, additional, LI, JIANPING, additional, HUANG, WEIJIAN, additional, FU, GUOSHENG, additional, LI, CHUNJIAN, additional, DONG, YUGANG, additional, WANG, CHUNSHENG, additional, ZHOU, XINMIN, additional, KONG, YE, additional, SOTOMAYOR, ARISTIDES, additional, ACCINI MENDOZA, JOSE LUIS, additional, CASTILLO, HENRY, additional, URINA, MIGUEL, additional, AROCA, GUSTAVO, additional, PEREZ, MARITZA, additional, MOLINA DE SALAZAR, DORA INES, additional, SANCHEZ VALLEJO, GREGORIO, additional, FERNANDO, MANZUR J, additional, GARCIA, HENRY, additional, GARCIA, LUIS HERNANDO, additional, ARCOS, EDGAR, additional, GOMEZ, JUAN, additional, CUERVO MILLAN, FRANCISCO, additional, TRUJILLO DADA, FREDY ALBERTO, additional, VESGA, BORIS, additional, MORENO SILGADO, GUSTAVO ADOLFO, additional, ZIDKOVA, EVA, additional, LUBANDA, JEAN-CLAUDE, additional, KALETOVA, MARKETA, additional, KRYZA, RADIM, additional, MARCINEK, GABRIEL, additional, RICHTER, MAREK, additional, SPINAR, JINDRICH, additional, MATUSKA, JIRI, additional, TESAK, MARTIN, additional, MOTOVSKA, ZUZANA, additional, BRANNY, MARIAN, additional, MALY, JIRI, additional, MALY, MARTIN, additional, WIENDL, MARTIN, additional, FOLTYNOVA CAISOVA, LENKA, additional, SLABY, JOSEF, additional, VOJTISEK, PETR, additional, PIRK, JAN, additional, SPINAROVA, LENKA, additional, BENESOVA, MIROSLAVA, additional, CANADYOVA, JULIA, additional, HOMZA, MIROSLAV, additional, FLORIAN, JINDRICH, additional, POLASEK, ROSTISLAV, additional, COUFAL, ZDENEK, additional, SKALNIKOVA, VLADIMIRA, additional, BRAT, RADIM, additional, BRTKO, MIROSLAV, additional, JANSKY, PETR, additional, LINDNER, JAROSLAV, additional, MARCIAN, PAVEL, additional, STRAKA, ZBYNEK, additional, TRETINA, MARTIN, additional, DUARTE, YAN CARLOS, additional, POW CHON LONG, FREDDY, additional, SANCHEZ, MAYRA, additional, LOPEZ, JOSE, additional, PERUGACHI, CARMITA, additional, MARMOL, RICARDO, additional, TRUJILLO, FREDDY, additional, TERAN, PABLO, additional, TUOMILEHTO, JAAKKO, additional, TUOMILEHTO, HENRI, additional, TUOMINEN, MARJA-LEENA, additional, KANTOLA, ILKKA, additional, STEG, GABRIEL, additional, ABOYANS, VICTOR, additional, LECLERCQ, FLORENCE, additional, FERRARI, EMILE, additional, BOCCARA, FRANCK, additional, MESSAS, EMMANUEL, additional, MISMETTI, PATRICK, additional, SEVESTRE, MARIE ANTOINETTE, additional, CAYLA, GUILLAUME, additional, MOTREFF, PASCAL, additional, STOERK, STEFAN, additional, DUENGEN, HANS-DIRK, additional, STELLBRINK, CHRISTOPH, additional, GUEROCAK, OSMAN, additional, KADEL, CHRISTOPH, additional, BRAUN-DULLAEUS, RUEDIGER, additional, JESERICH, MICHAEL, additional, OPITZ, CHRISTIAN, additional, VOEHRINGER, HANS-FRIEDRICH, additional, APPEL, KARL-FRIEDRICH, additional, WINKELMANN, BERNHARD, additional, DORSEL, THOMAS, additional, NIKOL, SIGRID, additional, DARIUS, HARALD, additional, RANFT, JURGEN, additional, SCHELLONG, SEBASTIAN, additional, JUNGMAIR, WOLFGANG, additional, DAVIERWALA, PIROZE, additional, VORPAHL, MARC, additional, BAJNOK, LASZLO, additional, LASZLO, ZOLTAN, additional, NOORI, EBRAHIM, additional, VERESS, GABOR, additional, VERTES, ANDRAS, additional, ZSARY, ANDRAS, additional, KIS, ERNO, additional, KORANYI, LASZLO, additional, BAKAI, JUDIT, additional, BODA, ZOLTAN, additional, POOR, FERENC, additional, JARAI, ZOLTAN, additional, KEMENY, VENDEL, additional, BARTON, JOHN, additional, MCADAM, BRENDAN, additional, MURPHY, ANDREW, additional, CREAN, PETER, additional, MAHON, NIALL, additional, CURTIN, RONAN, additional, MACNEILL, BRIAIN, additional, DINNEEN, SEAN, additional, HALABI, MAJDI, additional, ZIMLICHMAN, REUVEN, additional, ZELTSER, DAVID, additional, TURGEMAN, YOAV, additional, KLAINMAN, ELIEZER, additional, LEWIS, BASIL, additional, KATZ, AMOS, additional, ATAR, SHAUL, additional, NIKOLSKY, EUGENIA, additional, BOSI, STEFANO, additional, NALDI, MONICA, additional, FAGGIANO, POMPILIO, additional, ROBBA, DEBORA, additional, MOS, LUCIO, additional, SINAGRA, GIANFRANCO, additional, COSMI, FRANCO, additional, OLTRONA VISCONTI, LUIGI, additional, CARMINE, DE MATTEIS, additional, DI PASQUALE, GIUSEPPE, additional, DI BIASE, MATTEO, additional, MANDORLA, SARA, additional, BERNARDINANGELI, MARINO, additional, PICCINNI, GIOVANNI CARLO, additional, GULIZIA, MICHELE MASSIMO, additional, GALVANI, MARCELLO, additional, VENTURI, FLAVIO, additional, MOROCUTTI, GIORGIO, additional, BALDIN, MARIA GRAZIA, additional, OLIVIERI, CARLO, additional, PERNA, GIAN PIERO, additional, CIRRINCIONE, VINCENZO, additional, KANNO, TAKAYASU, additional, DAIDA, HIROYUKI, additional, OZAKI, YUKIO, additional, MIYAMOTO, NAOMASA, additional, HIGASHIUE, SHINICHI, additional, DOMAE, HIROSHI, additional, HOSOKAWA, SHINOBU, additional, KOBAYASHI, HIROO, additional, KURAMOCHI, TAKEHIKO, additional, FUJII, KENSHI, additional, MIZUTOMI, KAZUAKI, additional, SAKU, KEIJIRO, additional, KIMURA, KAZUO, additional, HIGUCHI, YOSHIHARU, additional, ABE, MITSUNORI, additional, OKUDA, HARUHITO, additional, NODA, TOSHIYUKI, additional, MITA, TERUAKI, additional, HIRAYAMA, ATSUSHI, additional, ONAKA, HARUHIKO, additional, INOKO, MORIAKI, additional, HIROKAMI, MITSUGU, additional, OKUBO, MUNENORI, additional, AKATSUKA, YUTAKA, additional, IMAMAKI, MIZUHO, additional, KAMIYA, HARUO, additional, MANITA, MAMORU, additional, HIMI, TOSHIHARU, additional, UENO, HIDEKI, additional, HISAMATSU, YUJI, additional, AKO, JUNYA, additional, NISHINO, YASUHIRO, additional, KAWAKAMI, HIDEO, additional, YAMADA, YUTAKA, additional, KORETSUNE, YUKIHIRO, additional, YAMADA, TAKAHISA, additional, YOSHIDA, TETSURO, additional, SHIMOMURA, HIDEKI, additional, KINOSHITA, NORIYUKI, additional, TAKAHASHI, AKIHIKO, additional, YUSOFF, KHALID, additional, WAN AHMAD, WAN AZMAN, additional, ABU HASSAN, MUHAMMAD RADZI, additional, KASIM, SAZZLI, additional, ABDUL RAHIM, AIZAI AZAN, additional, MOHD ZAMRIN, DIMON, additional, MACHIDA, MASAHARU, additional, HIGASHINO, YORIHIKO, additional, UTSU, NORIAKI, additional, NAKANO, AKIHIKO, additional, NAKAMURA, SHIGERU, additional, HASHIMOTO, TETSUO, additional, ANDO, KENJI, additional, SAKAMOTO, TOMOHIRO, additional, PRINS, F.J., additional, LOK, DIRK, additional, MILHOUS, JOHANNES GERT-JAN, additional, VIERGEVER, ERIC, additional, WILLEMS, FRANK, additional, SWART, HENK, additional, ALINGS, MARCO, additional, BREEDVELD, ROB, additional, DE VRIES, KEES-JAN, additional, VAN DER BORGH, ROGER, additional, OEI, FANNY, additional, ZOET-NUGTEREN, STIENEKE, additional, KRAGTEN, HANS, additional, HERRMAN, JEAN PAUL, additional, VAN BERGEN, PAUL, additional, GOSSELINK, MARCEL, additional, HOEKSTRA, EDUARD, additional, ZEGERS, ERWIN, additional, RONNER, EELKO, additional, DEN HARTOG, FRANK, additional, BARTELS, GERARD, additional, NIEROP, PETER, additional, VAN DER ZWAAN, COEN, additional, VAN ECK, JACOB, additional, VAN GORSELEN, EDWIN, additional, GROENEMEIJER, BJORN, additional, HOOGSLAG, PIETER, additional, DE GROOT, MARC ROBERT, additional, LOYOLA, ALDRIN, additional, SULIT, DENNIS JOSE, additional, REY, NANNETTE, additional, ABOLA, MARIA TERESA, additional, MORALES, DANTE, additional, PALOMARES, ELLEN, additional, ABAT, MARC EVANS, additional, ROGELIO, GREGORIO, additional, CHUA, PHILIP, additional, DEL PILAR, JOSE CARLO, additional, ALCARAZ, JOHN DENNIS, additional, EBO, GERALDINE, additional, TIRADOR, LOUIE, additional, CRUZ, JOSEFINA, additional, ANONUEVO, JOHN, additional, PITARGUE, ARTHUR, additional, JANION, MARIANNA, additional, GUZIK, TOMASZ, additional, GAJOS, GRZEGORZ, additional, ZABOWKA, MACIEJ, additional, RYNKIEWICZ, ANDRZEJ, additional, BRONCEL, MARLENA, additional, SZUBA, ANDRZEJ, additional, CZARNECKA, DANUTA, additional, MAGA, PAWEL, additional, STRAZHESKO, IRINA, additional, VASYUK, YURY, additional, SIZOVA, ZHANNA, additional, POZDNYAKOV, YURY, additional, BARBARASH, OLGA, additional, VOEVODA, MIKHAIL, additional, POPONINA, TATIANA, additional, REPIN, ALEXEY, additional, OSIPOVA, IRINA, additional, EFREMUSHKINA, ANNA, additional, NOVIKOVA, NINA, additional, AVERKOV, OLEG, additional, ZATEYSHCHIKOV, DMITRY, additional, VERTKIN, ARKADIY, additional, AUSHEVA, AZA, additional, COMMERFORD, PATRICK, additional, SEEDAT, SAADIYA, additional, VAN ZYL, LOUIS, additional, ENGELBRECHT, JAN, additional, MAKOTOKO, ELLEN MAKONLI, additional, PRETORIUS, CATHARINA ELIZABETH, additional, MOHAMED, ZAID, additional, HORAK, ADRIAN, additional, MABIN, THOMAS, additional, KLUG, ERIC, additional, BAE, JANG-HO, additional, KIM, CHEOLHO, additional, KIM, CHONG-JIN, additional, KIM, DONG-SOO, additional, KIM, YONG JIN, additional, JOO, SEUNGJAE, additional, HA, JONG-WON, additional, PARK, CHUL SOO, additional, KIM, JANG YOUNG, additional, KIM, YOUNG-KWON, additional, JARNERT, CHRISTINA, additional, MOOE, THOMAS, additional, DELLBORG, MIKAEL, additional, TORSTENSSON, INGEMAR, additional, ALBERTSSON, PER, additional, JOHANSSON, LARS, additional, AL-KHALILI, FARIS, additional, ALMROTH, HENRIK, additional, ANDERSSON, TOMMY, additional, PANTEV, EMIL, additional, TENGMARK, BENGT-OLOV, additional, LIU, BO, additional, RASMANIS, GUNDARS, additional, WAHLGREN, CARL-MAGNUS, additional, MOCCETTI, TIZIANO, additional, PARKHOMENKO, ALEXANDER, additional, TSELUYKO, VIRA, additional, VOLKOV, VOLODYMYR, additional, KOVAL, OLENA, additional, KONONENKO, LYUDMYLA, additional, PROKHOROV, OLEKSANDR, additional, VDOVYCHENKO, VALERIY, additional, BAZYLEVYCH, ANDRIY, additional, RUDENKO, LEONID, additional, VIZIR, VADYM, additional, KARPENKO, OLEKSANDR, additional, MALYNOVSKY, YAROSLAV, additional, KOVAL, VALENTYNA, additional, STOROZHUK, BORYS, additional, COTTON, JAMES, additional, VENKATARAMAN, ASOK, additional, MORIARTY, ANDREW, additional, CONNOLLY, DEREK, additional, DAVEY, PATRICK, additional, SENIOR, ROXY, additional, BIRDI, INDERPAUL, additional, CALVERT, JOHN, additional, DONNELLY, PATRICK, additional, TREVELYAN, JASPER, additional, CARTER, JUSTIN, additional, PEACE, AARON, additional, AUSTIN, DAVID, additional, KUKREJA, NEVILLE, additional, HILTON, THOMAS, additional, SRIVASTAVA, SUNNY, additional, WALSH, RONALD, additional, FIELDS, RONALD, additional, HAKAS, JOSEPH, additional, PORTNAY, EDWARD, additional, GOGIA, HARINDER, additional, SALACATA, ABRAHAM, additional, HUNTER, JOHN J., additional, BACHARACH, J MICHAEL, additional, SHAMMAS, NICOLAS, additional, SURESH, DAMODHAR, additional, SCHNEIDER, RICKY, additional, GURBEL, PAUL, additional, BANERJEE, SUBHASH, additional, GRENA, PAUL, additional, BEDWELL, NOEL, additional, SLOAN, STEPHEN, additional, LUPOVITCH, STEVEN, additional, SONI, ANAND, additional, GIBSON, KATHLEEN, additional, SANGRIGOLI, RENEE, additional, MEHTA, RAJENDRA, additional, I-HSUAN TSAI, PETER, additional, GILLESPIE, EVE, additional, DEMPSEY, STEPHEN, additional, HAMROFF, GLENN, additional, BLACK, ROBERT, additional, LADER, ELLIS, additional, KOSTIS, JOHN B., additional, BITTNER, VERA, additional, MCGUINN, WILLIAM, additional, BRANCH, KELLEY, additional, MALHOTRA, VINAY, additional, MICHAELSON, STEPHEN, additional, VACANTE, MICHAEL, additional, MCCORMICK, MATTHEW, additional, ARIMIE, RALUCA, additional, CAMP, ALAN, additional, DAGHER, GEORGE, additional, KOSHY, N. MATHEW, additional, THEW, STEPHEN, additional, COSTELLO, FREDERICK, additional, HEIMAN, MARK, additional, CHILTON, ROBERT, additional, MORAN, MICHAEL, additional, ADLER, FREDRIC, additional, COMEROTA, ANTHONY, additional, SEIWERT, ANDREW, additional, FRENCH, WILLIAM, additional, SEROTA, HARVEY, additional, HARRISON, ROBERT, additional, BAKAEEN, FAISAL, additional, OMER, SHUAB, additional, CHANDRA, LOKESH, additional, WHELAN, ALAN, additional, BOYLE, ANDREW, additional, ROBERTS-THOMSON, PHILIP, additional, ROGERS, JAMES, additional, CARROLL, PATRICK, additional, COLQUHOUN, DAVID, additional, SHAW, JAMES, additional, BLOMBERY, PETER, additional, AMERENA, JOHN, additional, HII, CHRIS, additional, ROYSE, ALISTAIR, additional, SINGH, BHUWAN, additional, SELVANAYAGAM, JOSEPH, additional, JANSEN, SHIRLEY, additional, LO, WINGCHI, additional, HAMMETT, CHRISTOPHER, additional, POULTER, ROHAN, additional, NARASIMHAN, SESHASAYEE, additional, WIGGERS, HENRIK, additional, NIELSEN, HENRIK, additional, GISLASON, GUNNAR, additional, KOBER, LARS, additional, HOULIND, KIM, additional, BOENELYKKE SOERENSEN, VIBEKE, additional, DIXEN, ULRIK, additional, REFSGAARD, JENS, additional, ZEUTHEN, ELISABETH, additional, SOEGAARD, PETER, additional, HRANAI, MARIAN, additional, GASPAR, LUDOVIT, additional, PELLA, DANIEL, additional, HATALOVA, KATARINA, additional, DROZDAKOVA, ERIKA, additional, COMAN, IOAN, additional, DIMULESCU, DOINA, additional, VINEREANU, DRAGOS, additional, CINTEZA, MIRCEA, additional, SINESCU, CRINA, additional, ARSENESCU, CATALINA, additional, BENEDEK, IMRE, additional, BOBESCU, ELENA, additional, DOBREANU, DAN, additional, GAITA, DAN, additional, IANCU, ADRIAN, additional, ILIESIU, ADRIANA, additional, LIGHEZAN, DANIEL, additional, PETRESCU, LUCIAN, additional, PIRVU, OCTAVIAN, additional, TEODORESCU, IULIA, additional, TESLOIANU, DAN, additional, VINTILA, MARIUS MARCIAN, additional, and CHIONCEL, OVIDIU, additional

Published
2018
Full Text
View/download PDF

197. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin

Author

Giugliano, Robert P., primary, Keech, Anthony, additional, Murphy, Sabina A., additional, Huber, Kurt, additional, Tokgozoglu, S. Lale, additional, Lewis, Basil S., additional, Ferreira, Jorge, additional, Pineda, Armando Lira, additional, Somaratne, Ransi, additional, Sever, Peter S., additional, Pedersen, Terje R., additional, and Sabatine, Marc S., additional

Published
2017
Full Text
View/download PDF

198. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

Author

Niessner, Alexander, primary, Tamargo, Juan, additional, Koller, Lorenz, additional, Saely, Christoph H, additional, Schmidt, Thomas Andersen, additional, Savarese, Gianluigi, additional, Wassmann, Sven, additional, Rosano, Giuseppe, additional, Ceconi, Claudio, additional, Torp-Pedersen, Christian, additional, Kaski, Juan Carlos, additional, Kjeldsen, Keld Per, additional, Agewall, Stefan, additional, Walther, Thomas, additional, Drexel, Heinz, additional, and Lewis, Basil S, additional

Published
2017
Full Text
View/download PDF

199. Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE)

Author

Punthakee, Zubin, Gerstein, Hertzel C., Bosch Pagans, Jordi, Tyrwhitt, Jessica, Jung, Hyejung, Lee, Shun Fu, Lonn, Eva, Marsden, Tamara, McKelvie, Robert, McQueen, Matthew J., Morillo, Carlos, Yusuf, Shazzid, Dagenais, Gilles, Diaz, Rafael, Maggioni, Aldo P., Probstfield, Jeffrey, Ramachandran, Ambady, Riddle, Matthew C., Rydén, Lars, Badings, Erik, Birkeland, Kare, Cardona Munoz, Ernesto G., Commerford, Patrick, Davies, Melanie, Fodor, George J., Gomis, Ramon, Hanefeld, Markolf, Hildebrandt, Per, Kacerovsky Bielesz, Gertrud, Keltai, Matyas, Lanas, Fernando, Lewis, Basil S., Lopez-Jaramillo, Patricio, Marin Neto, Jose Antonio, Marre, Michel, Mendoza, Ivan, Pan, Chun yue, Pirags, Valdis, Rosenstock, Julio, Spinas, Giatgen A., Sreenan, Seamus, Syvänne, Mikko, Yale, Jean Francois, and ORIGIN Trial Investigators

Subjects
Omega-3, Fatty Acids, Insulin Glargine, Postintervention, Cardiovascular
Abstract

8 p., OBJECTIVE The Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial reported neutral effects of insulin glargine on cardiovascular outcomes and cancers and reduced incident diabetes in high–cardiovascular risk adults with dysglycemia after 6.2 years of active treatment. Omega-3 fatty acids had neutral effects on cardiovascular outcomes. The ORIGIN and Legacy Effects (ORIGINALE) study measured posttrial effects of these interventions during an additional 2.7 years. RESEARCH DESIGN AND METHODS Surviving ORIGIN participants attended up to two additional visits. The hazard of clinical outcomes during the entire follow-up period from randomization was calculated. RESULTS Of 12,537 participants randomized, posttrial data were analyzed for 4,718 originally allocated to insulin glargine (2,351) versus standard care (2,367), and 4,771 originally allocated to omega-3 fatty acid supplements (2,368) versus placebo (2,403). Posttrial, small differences in median HbA1c persisted (glargine 6.6% [49 mmol/mol], standard care 6.7% [50 mmol/mol], P = 0.025). From randomization to the end of posttrial follow-up, no differences were found between the glargine and standard care groups in myocardial infarction, stroke, or cardiovascular death (1,185 vs. 1,165 events; hazard ratio 1.01 [95% CI 0.94–1.10]; P = 0.72); myocardial infarction, stroke, cardiovascular death, revascularization, or hospitalization for heart failure (1,958 vs. 1,910 events; 1.03 [0.97–1.10]; P = 0.38); or any cancer (524 vs. 529 events; 0.99 [0.88–1.12]; P = 0.91) or between omega-3 and placebo groups in cardiovascular death (688 vs. 700; 0.98 [0.88–1.09]; P = 0.68) or other outcomes. CONCLUSIONS During >6 years of treatment followed by >2.5 years of observation, insulin glargine had neutral effects on health outcomes and salutary effects on metabolic control, whereas omega-3 fatty acid supplementation had no effect.

Published
2016

200. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Author

Lonn, Eva M, Bosch, Jackie, López-Jaramillo, Patricio, Zhu, Jun, Liu, Lisheng, Pais, Prem, Diaz, Rafael, Xavier, Denis, Sliwa, Karen, Dans, Antonio, Avezum, Álvaro, Piegas, Leopoldo S, Keltai, Katalin, Keltai, Matyas, Chazova, Irina, Peters, Ron JG, Held, Claes, Yusoff, Khalid, Lewis, Basil S, Jansky, Petr, Parkhomenko, Alexander, Khunti, Kamlesh, Toff, William D, Reid, Christopher M, Varigos, John, Leiter, Lawrence A, Molina, Dora I, McKelvie, Robert, Pogue, Janice, Wilkinson, Joanne, Jung, Hyejung, Dagenais, Gilles, Department of Medicine, and Faculty of Health Sciences

Subjects
Male, Incidence, Tetrazoles, Blood Pressure, Kaplan-Meier Estimate, Middle Aged, Hydrochlorothiazide, candesartan, Double-Blind Method, Cardiovascular Diseases, Risk Factors, Hypertension, Humans, Benzimidazoles, Drug Therapy, Combination, Female, Hypotension, Antihypertensive Agents, Aged
Abstract

Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its role in persons at intermediate risk and with lower blood pressure is unclear. In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to receive either candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke; the second coprimary outcome additionally included resuscitated cardiac arrest, heart failure, and revascularization. The median follow-up was 5.6 years. The mean blood pressure of the participants at baseline was 138.1/81.9 mm Hg; the decrease in blood pressure was 6.0/3.0 mm Hg greater in the active-treatment group than in the placebo group. The first coprimary outcome occurred in 260 participants (4.1%) in the active-treatment group and in 279 (4.4%) in the placebo group (hazard ratio, 0.93; 95% confidence interval [CI], 0.79 to 1.10; P=0.40); the second coprimary outcome occurred in 312 participants (4.9%) and 328 participants (5.2%), respectively (hazard ratio, 0.95; 95% CI, 0.81 to 1.11; P=0.51). In one of the three prespecified hypothesis-based subgroups, participants in the subgroup for the upper third of systolic blood pressure (>143.5 mm Hg) who were in the active-treatment group had significantly lower rates of the first and second coprimary outcomes than those in the placebo group; effects were neutral in the middle and lower thirds (P=0.02 and P=0.009, respectively, for trend in the two outcomes). Therapy with candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day was not associated with a lower rate of major cardiovascular events than placebo among persons at intermediate risk who did not have cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; ClinicalTrials.gov number, NCT00468923.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results